// Auto-generated - do not edit
export const substanceName = "Propofol";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Propofol.md","displayName":"DrugBank","size":22946},{"id":"protestkit","fileName":"PROTESTKIT - Propofol.json","displayName":"Protest Kit","size":1594},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Propofol.md","displayName":"TripSit Factsheets","size":1413},{"id":"wikipedia","fileName":"WIKIPEDIA - Propofol.md","displayName":"Wikipedia","size":16494}];
export const contents: Record<string, string> = {
  "drugbank": `# Propofol
*Source: https://go.drugbank.com/drugs/DB00818*

## Overview

### Description

This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.

### Background

Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.

### Indication

Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus.

### Pharmacodynamics

Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit beta-2
Potentiator
Gamma-aminobutyric acid receptor subunit beta-3
Potentiator
GABA(A) Receptor
Positive allosteric modulator

### Absorption

Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes.

### Metabolism

Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol.
Hover over products below to view reaction partners
Propofol
4-Hydroxypropofol
4-Quinol sulfate
1-Quinol glucuronide
Propofol glucuronide
1-Quinol glucuronide
4-OH-propofol

### Half-life

Initial distribution phase t
1/2α
=1.8-9.5 minutes. Second redistirubtion phase t
1/2β
=21-70 minutes. Terminal elimination phase t
1/2γ
=1.5-31 hours.

### Toxicity

Overdosage may increase pharmacologic and adverse effects or cause death.
IV LD
50
=53 mg/kg (mice), 42 mg/kg (rats). Oral LD
50
(as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Propofol is combined with 1,2-Benzodiazepine.
Abacavir
The metabolism of Abacavir can be decreased when combined with Propofol.
Abaloparatide
The risk or severity of adverse effects can be increased when Propofol is combined with Abaloparatide.
Abametapir
The serum concentration of Propofol can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Propofol can be increased when combined with Abatacept.

### Food Interactions

No interactions found.

## Chemical Information

**DrugBank ID:** DB00818

**Synonyms:** 2,6-bis(1-methylethyl)phenol
2,6-Diisopropylphenol
Propofol
Propofolum

**Chemical Formula:** C
12
H
18
O

**SMILES:** CC(C)C1=CC=CC(C(C)C)=C1O

**Weight:** Average: 178.2707
Monoisotopic: 178.135765198

**IUPAC Name:** 2,6-bis(propan-2-yl)phenol

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
CA2212794
No
2000-09-12
2015-03-17
Canada
US8476010
Yes
2013-07-02
2025-06-01
US
US5908869
Yes
1999-06-01
2015-09-22
US
US5731356
Yes
1998-03-24
2015-09-22
US
US5731355
Yes
1998-03-24
2015-09-22
US
US5714520
Yes
1998-02-03
2015-09-22
US

### Indicated Conditions

0

### Phase 0

13

### Phase 1

84

### Phase 2

121

### Phase 3

136

### Phase 4

529

### Therapeutic Categories

Anesthetics,
General

### Summary

Propofol
is a medication used in general anesthesia and for sedation.

### Brand Names

Diprivan

### Generic Name

Propofol

### DrugBank Accession Number

DB00818

### Groups

Approved, Investigational, Vet approved

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Propofol (DB00818)
×
Close

### External IDs

ICI 35-868
ICI 35,868
ICI 35868
ICI-35868
ICI35,868

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Associated Therapies

Induction of anesthesia therapy
Maintenance of anesthesia therapy
Monitored anesthesia care sedation
Sedative therapy

### Mechanism of action

The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit beta-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit beta-3
potentiator
Humans
A
GABA(A) Receptor
positive allosteric modulator
Humans
U
Sodium channel protein type 4 subunit alpha
inhibitor
Humans
U
Sodium channel protein type 2 subunit alpha
inhibitor
Humans

### Volume of distribution

60 L/kg [healthy adults]

### Protein binding

95 to 99%, primarily to serum albumin and hemoglobin

### Route of elimination

It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.

### Clearance

23 - 50 mL/kg/min
1.6 - 3.4 L/min [70 Kg adults]

### International/Other Brands

Anepol (Ha Na Pharm)
/
Anespro (Behrens)
/
Anesvan (Chi Sheng)
/
Critifol (Abbott)
/
Disoprivan (AstraZeneca)
/
Disoprofol
/
Dormofol (Actavis)
/
Fresofol (Boryung)
/
Gobbifol (Gobbi)
/
Hipnolam (AC Farma)
/
Hypro (Celon)
/
IV-Pro (Claris Lifesciences)
/
Lipuro (B. Braun Medical)
/
Oleo-Lax (Fada)
/
Plofed (Warsaw Pharmaceutical Works)
/
Profol (Biogalenic)
/
Profolen (Blausiegel)
/
Propofabb (Hospira)
/
Propofil (Alvia)
/
Propogen (Genepharm)
/
Propolipid (Fresenius)
/
Propovan (Bharat Serums)
/
Propoven (Fresenius)
/
Provive (AFT)
/
Rapinovet
/
Recofol (Bayer)
/
Safol (Novell)
/
Trivam (Hana Pharm)
/
Troypofol (Troikaa)
/
Unifol (Claris Lifesciences)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Fresenius Kabi Italia S.R.L.
2020-01-13
Not applicable
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Astrazeneca Ab
1996-06-24
2010-10-31
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
Fresenius Kabi Italia S.R.L.
2009-11-17
Not applicable
US
Diprivan
Injection, emulsion
10 mg/1mL
Intravenous
General Injectables & Vaccines, Inc
2010-03-01
Not applicable
US
Diprivan 1%
Emulsion
10 mg / mL
Intravenous
Aspen Pharmacare Canada Inc.
1993-12-31
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Amneal Pharmaceuticals LLC
2024-08-16
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
A-S Medication Solutions
2016-01-07
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Civica, Inc.
2020-09-03
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
NorthStar Rx LLC
2022-07-01
Not applicable
US
Propofol
Injection, emulsion
10 mg/1mL
Intravenous
Pfizer Laboratories Div Pfizer Inc
2020-10-05
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Anesthesia S/I-40
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-08-24
Not applicable
US
Anesthesia S/I-50
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-06-16
2018-12-14
US
Anesthesia S/I-60
Propofol
(10 mg/1mL)
+
Isopropyl alcohol
(0.7 mL/1mL)
Injection, emulsion; Kit
Intravenous; Topical
RX PHARMA-PACK, INC.
2017-06-16
Not applicable
US

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Fresenius Propoven 2%
Propofol
(20 mg/1mL)
Emulsion
Intravenous
Fresenius Kabi Italia S.R.L.
2020-06-05
Not applicable
US
Fresenius Propoven 2%
Propofol
(20 mg/1mL)
Emulsion
Intravenous
Fresenius Kabi Italia S.R.L.
2020-06-05
Not applicable
US
PROPOFOL % 1 FRESENIUS 10 GR 20 ML AMPUL, 5 ADET
Propofol
(1 %)
Emulsion
Intravenous
FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.
2013-01-29
2022-11-03
Turkey
Propofol 1%
Propofol
(10 mg/1mL)
Injection, emulsion
Intravenous
Genixus
2023-03-29
Not applicable
US
Propofol Lipuro
Propofol
(10 mg/1mL)
Injection, emulsion
Intravenous
B. Braun Medical Inc.
2021-03-12
Not applicable
US

### ATC Codes

N01AX10 — Propofol
N01AX — Other general anesthetics
N01A — ANESTHETICS, GENERAL
N01 — ANESTHETICS
N — NERVOUS SYSTEM

### Drug Categories

Agents Causing Muscle Toxicity
Agents that produce hypertension
Agents that reduce seizure threshold
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Benzene Derivatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)
Cytochrome P-450 CYP2B6 Substrates
Cytochrome P-450 CYP2C18 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C8 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2E1 Inhibitors
Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors
Cytochrome P-450 CYP3A4 Inhibitors (weak)
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Hypnotics and Sedatives
Hypotensive Agents
Miscellaneous General Anesthetics
Nervous System
P-glycoprotein inducers
Phenols
Potential QTc-Prolonging Agents
QTc Prolonging Agents
UGT1A1 Inhibitors
UGT1A1 Substrates
UGT1A6 substrate
UGT1A9 Substrates

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Cumenes
Direct Parent
Cumenes
Alternative Parents
Phenylpropanes
/
1-hydroxy-4-unsubstituted benzenoids
/
Organooxygen compounds
/
Hydrocarbon derivatives
Substituents
1-hydroxy-4-unsubstituted benzenoid
/
Aromatic homomonocyclic compound
/
Cumene
/
Hydrocarbon derivative
/
Organic oxygen compound
/
Organooxygen compound
/
Phenol
/
Phenylpropane
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols (
CHEBI:44915
)
/
a small molecule (
CPD-11437
)

### Kingdom

Organic compounds

### Super Class

Benzenoids

### Class

Benzene and substituted derivatives

### Sub Class

Cumenes

### Direct Parent

Cumenes

### Alternative Parents

Phenylpropanes
/
1-hydroxy-4-unsubstituted benzenoids
/
Organooxygen compounds
/
Hydrocarbon derivatives

### Substituents

1-hydroxy-4-unsubstituted benzenoid
/
Aromatic homomonocyclic compound
/
Cumene
/
Hydrocarbon derivative
/
Organic oxygen compound
/
Organooxygen compound
/
Phenol
/
Phenylpropane

### Molecular Framework

Aromatic homomonocyclic compounds

### External Descriptors

phenols (
CHEBI:44915
)
/
a small molecule (
CPD-11437
)

### Affected organisms

Humans and other mammals

### UNII

YI7VU623SF

### CAS number

2078-54-8

### InChI Key

OLBCVFGFOZPWHH-UHFFFAOYSA-N

### InChI

InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3

### Synthesis Reference

John R. Carpenter, "Propofol-based anesthetic and method of making same." U.S. Patent US6150423, issued May, 1977.
US6150423

### General References

Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. [
Article
]
Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. [
Article
]
Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Jun;25(6):460-7. doi: 10.1017/S026502150800375X. Epub 2008 Feb 26. [
Article
]
FDA Approved Drug Products: DIPRIVAN (propofol) injectable emulsion for intravenous use [
Link
]

### External Links

Human Metabolome Database
HMDB0014956
KEGG Drug
D00549
KEGG Compound
C07523
PubChem Compound
4943
PubChem Substance
46504991
ChemSpider
4774
BindingDB
50058046
RxNav
8782
ChEBI
44915
ChEMBL
CHEMBL526
ZINC
ZINC000000968303
Therapeutic Targets Database
DAP000662
PharmGKB
PA451141
PDBe Ligand
PFL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Propofol

### Human Metabolome Database

HMDB0014956

### KEGG Drug

D00549

### KEGG Compound

C07523

### PubChem Compound

4943

### PubChem Substance

46504991

### ChemSpider

4774

### BindingDB

50058046

### RxNav

8782

### ChEBI

44915

### ChEMBL

CHEMBL526

### ZINC

ZINC000000968303

### Therapeutic Targets Database

DAP000662

### PharmGKB

PA451141

### PDBe Ligand

PFL

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Propofol

### PDB Entries

1e7a
/
3p50
/
5muo
/
5mur
/
5mvm
/
5mvn
/
5mzr
/
6x3t
/
8uc7
/
9bc6

### FDA label

Download
(168 KB)

### MSDS

Download
(71.9 KB)

### Manufacturers

App pharmaceuticals llc
Bedford laboratories div ben venue laboratories inc
Hospira inc
Teva parenteral medicines inc

### Packagers

APP Pharmaceuticals
AstraZeneca Inc.
Baxter International Inc.
Cardinal Health
Hospira Inc.
Pfizer Inc.
Sicor Pharmaceuticals
Teva Pharmaceutical Industries Ltd.

### Dosage Forms

Form
Route
Strength
Injection, emulsion; kit
Intravenous; Topical
Emulsion
20.000 mg
Emulsion
Intravenous; Parenteral
10 MG/ML
Emulsion
Parenteral
1.000 g
Injection
Parenteral
200 mg/20ml
Emulsion
Intravenous
500 mg
Solution
Parenteral
20 mg
Injection
Intravenous
Emulsion
200 mg
Suspension
Intravenous
10 mg
Emulsion
Intravenous
20 mg/1mL
Emulsion
Intravenous
0.2 g
Emulsion
Parenteral
0.200 g
Injection, emulsion
Intravenous
1 %
Emulsion
20 mg/1ml
Emulsion
Intravenous
2 %
Emulsion
Parenteral
200 mg
Emulsion
Intravenous
500.00 mg
Emulsion
Intravenous
0.5 g
Injection
Parenteral
200 mg
Emulsion
Intravenous
200 mg/20ml
Emulsion
Parenteral
10 mg/1ml
Injection
Parenteral
10 mg
Injection, emulsion
Intravenous
10 mg/1mL
Injection, emulsion
Intravenous
Injection, solution
Intravenous
Emulsion
Intravenous
1 %
Emulsion
Parenteral
Emulsion
Intravenous
10 mg
Emulsion
Intravenous
1 g
Injection
Intravenous
1 %
Emulsion
Parenteral
5 MG/ML
Injection, emulsion
Parenteral
Injection, emulsion
Intravenous
1 % w/v
Injection
Intravenous
1000 mg/100ml
Injection
Intravenous
200 mg/20ml
Injection
Intravenous
500 mg/50ml
Injection, emulsion
Intravenous
10 MG/ML
Injection, emulsion
Intravenous
20 MG/ML
Emulsion
Intravenous
10 mg / mL
Emulsion
10 MG/ML
Emulsion
20 MG/ML
Emulsion
Intravenous
100 mg
Emulsion
Intravenous
200 mg
Injection, solution
Intravenous
1 %
Injection, emulsion
Intravenous
2 %
Emulsion
Intravenous
20.0 mg/ml
Emulsion
Intravenous
10 mg/ml
Emulsion
Parenteral
1 %
Injection
Intravenous
10 mg/1mL
Emulsion
10 mg
Emulsion
Parenteral
10 mg
Emulsion
Intravenous
200.00 mg
Emulsion
Intravenous
220.000 mg
Emulsion
Intravenous
10.000 mg
Injection
Parenteral
10 MG/ML
Injection
Parenteral
20 MG/ML
Injection
Intravenous
10 mg/ml
Injection
Intravenous
20 mg/ml
Emulsion
Parenteral
10 MG/ML
Emulsion
Parenteral
20 MG/ML
Injection
Intravenous
10 mg
Injection
Intravenous
1 % w/v
Emulsion
Intravenous
200.000 mg
Injection, emulsion
Parenteral
10 mg/1ml
Emulsion
10 mg/1ml
Solution
Parenteral
10 mg/1ml

### Prices

Unit description
Cost
Unit
Diprivan 10 mg/ml vial
0.93USD
ml
Propoven 1000 mg/100 ml vial
0.19USD
ml
Propoven 200 mg/20 ml ampul
0.19USD
ml
Propoven 500 mg/50 ml vial
0.19USD
ml
Propofol 10 mg/ml vial
0.13USD
ml
Propofol 1% emulsion vial
0.1USD
ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Liquid

### Experimental Properties

Property
Value
Source
melting point (°C)
18 °C
PhysProp
boiling point (°C)
256 °C
PhysProp
water solubility
124 mg/L
Not Available
logP
3.79
HANSCH,C ET AL. (1995)
pKa
11.1 (at 20 °C)
SERJEANT,EP & DEMPSEY,B (1979)

### Predicted Properties

Property
Value
Source
Water Solubility
0.158 mg/mL
ALOGPS
logP
3.81
ALOGPS
logP
4.16
Chemaxon
logS
-3
ALOGPS
pKa (Strongest Acidic)
10.98
Chemaxon
pKa (Strongest Basic)
-5
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
1
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
20.23 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
56.42 m
3
·mol
-1
Chemaxon
Polarizability
21.61 Å
3
Chemaxon
Number of Rings
1
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9955
Blood Brain Barrier
+
0.9381
Caco-2 permeable
+
0.9153
P-glycoprotein substrate
Non-substrate
0.722
P-glycoprotein inhibitor I
Non-inhibitor
0.9343
P-glycoprotein inhibitor II
Non-inhibitor
0.9883
Renal organic cation transporter
Non-inhibitor
0.9036
CYP450 2C9 substrate
Non-substrate
0.7352
CYP450 2D6 substrate
Substrate
0.7838
CYP450 3A4 substrate
Non-substrate
0.5667
CYP450 1A2 substrate
Inhibitor
0.9107
CYP450 2C9 inhibitor
Non-inhibitor
0.907
CYP450 2D6 inhibitor
Non-inhibitor
0.9368
CYP450 2C19 inhibitor
Non-inhibitor
0.9026
CYP450 3A4 inhibitor
Non-inhibitor
0.9196
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.7429
Ames test
Non AMES toxic
0.9282
Carcinogenicity
Non-carcinogens
0.7195
Biodegradation
Not ready biodegradable
0.7808
Rat acute toxicity
2.2996 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8987
hERG inhibition (predictor II)
Non-inhibitor
0.9087
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(7.9 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-01t9-4900000000-9238ef924bbbfe181bdc
Mass Spectrum (Electron Ionization)
MS
splash10-03di-2900000000-52d81dde2dccf378a450
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00p3-5900000000-e3008f7936e6fcb4adf4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-04f09f9f4a3445558294
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-2c71e9f6e685d8c70f07
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-c0e80503d12f3dfff04c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-016u-9700000000-ef93fecf64d272efa702
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-9500000000-a634b354ccb9caec6720
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00p3-5900000000-e3008f7936e6fcb4adf4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-04f09f9f4a3445558294
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-2c71e9f6e685d8c70f07
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-0900000000-c0e80503d12f3dfff04c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-016u-9700000000-ef93fecf64d272efa702
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-014i-9500000000-a634b354ccb9caec6720
1H NMR Spectrum
1D NMR
Not Applicable
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
149.0734608
predicted
DarkChem Lite v0.1.0
[M-H]-
138.5598058
predicted
DarkChem Lite v0.1.0
[M-H]-
148.7001608
predicted
DarkChem Lite v0.1.0
[M-H]-
144.76744
predicted
DeepCCS 1.0 (2019)
[M-H]-
149.0734608
predicted
DarkChem Lite v0.1.0
[M-H]-
138.5598058
predicted
DarkChem Lite v0.1.0
[M-H]-
148.7001608
predicted
DarkChem Lite v0.1.0
[M-H]-
144.76744
predicted
DeepCCS 1.0 (2019)
[M+H]+
148.8474608
predicted
DarkChem Lite v0.1.0
[M+H]+
144.6142271
predicted
DarkChem Lite v0.1.0
[M+H]+
149.0566608
predicted
DarkChem Lite v0.1.0
[M+H]+
147.26515
predicted
DeepCCS 1.0 (2019)
[M+H]+
148.8474608
predicted
DarkChem Lite v0.1.0
[M+H]+
144.6142271
predicted
DarkChem Lite v0.1.0
[M+H]+
149.0566608
predicted
DarkChem Lite v0.1.0
[M+H]+
147.26515
predicted
DeepCCS 1.0 (2019)
[M+Na]+
149.1342608
predicted
DarkChem Lite v0.1.0
[M+Na]+
150.9871662
predicted
DarkChem Lite v0.1.0
[M+Na]+
148.6840608
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.7483
predicted
DeepCCS 1.0 (2019)
[M+Na]+
149.1342608
predicted
DarkChem Lite v0.1.0
[M+Na]+
150.9871662
predicted
DarkChem Lite v0.1.0
[M+Na]+
148.6840608
predicted
DarkChem Lite v0.1.0
[M+Na]+
155.7483
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inducer

### General Function

Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)

### Specific Function

ABC-type xenobiotic transporter activity

### Gene Name

ABCB1

### Uniprot ID

P08183

### Uniprot Name

ATP-dependent translocase ABCB1

### Molecular Weight

141477.255 Da

### Curator comments

Current data available supporting this enzyme action are in vitro studies.

`,
  "protestkit": `{
  "url": "https://drugs.tripsit.me/propofol",
  "experiencesUrl": "https://www.reddit.com/search/?q=Propofol",
  "name": "Propofol",
  "aliases": [
    "diprivan",
    "milk-of-amnesia"
  ],
  "aliasesStr": "diprivan,milk-of-amnesia",
  "summary": "A very short acting sedative that is usually given at the start of general anesthesia, and for maintenance of the prior. It should never be used outside of a medical setting. With that in mind, if you do plan to use this drug recreational, please have a very experienced friend with you that has the skills to insert a cannula, and monitor you very closely.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": []
  },
  "toxicity": null,
  "addictionPotential": null,
  "tolerance": null,
  "crossTolerances": null,
  "roas": [
    {
      "name": "Intravenous",
      "dosage": [
        {
          "name": "Light",
          "value": "10-30mg"
        },
        {
          "name": "Common",
          "value": "30-60mg"
        },
        {
          "name": "Strong",
          "value": "60-100mg"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.0 - 0.03 hours"
        },
        {
          "name": "Duration",
          "value": "0.17 - 0.33 hours"
        },
        {
          "name": "After effects",
          "value": "1.0 - 3.0 hours"
        }
      ]
    }
  ],
  "interactions": null,
  "effects": null,
  "categorized_effects": {
    "Physical effects": [],
    "Mental effects": [],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Propofol
*Source: TripSit Factsheets (tripsit.me)*

## Summary

A very short-acting sedative that is usually given at the start of general anesthesia and for maintenance of the prior. This drug is extremely dangerous to use outside of medical settings If one is to use this drug outside of a medical setting, it is strongly recommended having another experienced individual in-person to monitor ones pulse and breathing among other concerns.

## Classification
- **Categories:** depressant, habit-forming
- **Also known as:** milk-of-amnesia, diprivan

## Dosage

### Intravenous
- **Common:** 30-60mg
- **Light:** 10-30mg
- **Strong:** 60-100mg

*Note:  Note: These dosages are extremely tentative. The drug has a high risk outside of medical settings, extensive research is strongly recommended.*

## Duration
- **Onset:** minutes
- **Duration:** minutes
- **After Effects:** hours

## Additional Information
- **Avoid:** If in a non-hospital setting, nearly all substances should be avoided. If one is to use this drug outside of a medical setting, it is strongly recommended having another experienced individual in-person to monitor ones pulse and breathing among other concerns. If your pulse drops below 50, or if you are taking less than 10 breaths per minute, it is strongly recommended to call an ambulance. In some cases the user's body may be discoloured, in which case they are likely unconscious.
`,
  "wikipedia": `# Propofol
*Source: https://en.wikipedia.org/wiki/Propofol*

Propofol is the active component of an intravenous anesthetic formulation used for induction and maintenance of general anesthesia. The formulation was approved under the brand name Diprivan. Numerous generic versions have since been released. Intravenous administration is used to induce unconsciousness, after which anesthesia may be maintained using a combination of medications. It is manufactured as part of a sterile injectable emulsion formulation using soybean oil and lecithin, giving it a white milky coloration.
Compared to other anesthetic agents, recovery from propofol-induced anesthesia is generally rapid and associated with less frequent side effects (e.g., drowsiness, nausea, vomiting). Propofol may be used prior to diagnostic procedures requiring anesthesia, in the management of refractory status epilepticus, and for induction or maintenance of anesthesia prior to and during surgeries. It may be administered as a bolus or an infusion, or as a combination of the two.
First synthesized in 1973 by John B. Glen, a British veterinary anesthesiologist working for Imperial Chemical Industries (ICI, later AstraZeneca), propofol was introduced for therapeutic use as a lipid emulsion in the United Kingdom and New Zealand in 1986. Propofol (Diprivan) received FDA approval in October 1989. It is on the World Health Organization's List of Essential Medicines.

## Uses

### Anesthesia

To induce general anesthesia, propofol is the drug used almost exclusively, having largely replaced sodium thiopental.
It is often administered as part of an anesthesia maintenance technique called total intravenous anesthesia, using either manually programmed infusion pumps or computer-controlled infusion pumps in a process called target controlled infusion (TCI).
Propofol is also used to sedate people who are receiving mechanical ventilation but not undergoing surgery, such as patients in the intensive care unit. In critically ill patients, propofol is superior to lorazepam both in effectiveness and overall cost. Propofol is relatively inexpensive compared to medications of similar use due to shorter ICU stay length. One of the reasons propofol is thought to be more effective (although it has a longer half-life than lorazepam) is that studies have found that benzodiazepines like midazolam and lorazepam tend to accumulate in critically ill patients, prolonging sedation.
Propofol has also been suggested as a sleep aid in critically ill adults in an ICU setting; however, the effectiveness of this medicine in replicating the mental and physical aspects of sleep for people in the ICU is not clear.
Propofol can be administered via a peripheral IV or central line. Propofol is often paired with fentanyl (for pain relief) in intubated and sedated people. The two drugs are molecularly compatible in an IV mixture form.
Propofol is also used to deepen anesthesia to relieve laryngospasm. It may be used alone or followed by succinylcholine. Its use can avoid the need for paralysis and in some instances the potential side-effects of succinylcholine.

### Routine procedural sedation

Propofol is safe and effective for gastrointestinal endoscopy procedures (colonoscopies etc.). Its use in these settings results in a faster recovery compared to midazolam. It can also be combined with opioids or benzodiazepines. Because of its rapid induction and recovery time, propofol is also widely used for sedation of infants and children undergoing MRI procedures. It is also often used in combination with ketamine with minimal side effects.

### COVID-19

In March 2021, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Propofol‐Lipuro 1% to maintain sedation via continuous infusion in people older than sixteen with suspected or confirmed COVID-19 who require mechanical ventilation in an intensive care unit ICU setting. During the public health emergency, it was considered unfeasible to limit Fresenius Propoven 2% Emulsion or Propofol-Lipuro 1% to patients with suspected or confirmed COVID-19, so it was made available to all ICU patients under mechanical ventilation. This EUA has since been revoked.

### Status epilepticus

Status epilepticus may be defined as seizure activity lasting beyond five minutes and needing anticonvulsant medication. Several guidelines recommend the use of propofol for the treatment of refractory status epilepticus.

### Other uses

#### Assisted death in Canada

A lethal dose of propofol is used for medical assistance in dying in Canada to quickly induce deep coma and death, but rocuronium is always given as a paralytic ensuring death, even when the patient has died as a result of initial propofol overdose.

#### Capital punishment

The use of propofol as part of an execution protocol has been considered, although no person has been executed using this agent. This is largely due to European manufacturers and governments banning the export of propofol for such use.

#### Recreational use

Recreational use of the drug via self-administration has been reported but is relatively rare due to its potency and the level of monitoring required for safe use. Critically, a steep dose-response curve makes recreational use of propofol very dangerous, and deaths from self-administration continue to be reported. The short-term effects sought via recreational use include mild euphoria, hallucinations, and disinhibition.
Recreational use of the drug has been described among medical staff, such as anesthetists who have access to the drug. It is reportedly more common among anesthetists on rotations with short rest periods, as usage generally produces a well-rested feeling. Long-term use has been reported to result in addiction.
Attention to the risks of off-label use of propofol increased in August 2009, after the release of the Los Angeles County coroner's report that musician Michael Jackson was killed by a mixture of propofol and the benzodiazepine drugs lorazepam, midazolam, and diazepam on 25 June 2009. According to a 22 July 2009 search warrant affidavit unsealed by the district court of Harris County, Texas, Jackson's physician, Conrad Murray, administered 25 milligrams of propofol diluted with lidocaine shortly before Jackson's death.

## Manufacturing

Propofol as a commercial sterile emulsified formulation is considered difficult to manufacture.
It was initially formulated in Cremophor for human use, but this original formulation was implicated in an unacceptable number of anaphylactic events. It was eventually manufactured as a 1% emulsion in soybean oil. Sterile emulsions represent complex formulation, the stability of which is  dependent on the interplay of many factors such as micelle size and distribution.

## Side effects

One of propofol's most common side effects is pain on injection, especially in smaller veins. This pain arises from activation of the pain receptor, TRPA1, found on sensory nerves and can be mitigated by pretreatment with lidocaine. Less pain is experienced when infused at a slower rate in a large vein (antecubital fossa). Patients show considerable variability in their response to propofol, at times showing profound sedation with small doses.
Additional side effects include low blood pressure related to vasodilation, transient apnea following induction doses, and cerebrovascular effects. Propofol has more pronounced hemodynamic effects relative to many intravenous anesthetic agents. Reports of blood pressure drops of 30% or more are thought to be at least partially due to inhibition of sympathetic nerve activity. This effect is related to the dose and rate of propofol administration. It may also be potentiated by opioid analgesics.
Propofol can also cause decreased systemic vascular resistance, myocardial blood flow, and oxygen consumption, possibly through direct vasodilation. There are also reports that it may cause green discoloration of the urine.
Although propofol is widely used in the adult ICU setting, the side effects associated with medication seem to be more concerning in children. In the 1990s, multiple reported deaths of children in ICUs associated with propofol sedation prompted the FDA to issue a warning.
As a respiratory depressant, propofol frequently produces apnea. The persistence of apnea can depend on factors such as premedication, dose administered, and rate of administration, and may sometimes persist for longer than 60 seconds.  Possibly as the result of depression of the central inspiratory drive, propofol may produce significant decreases in respiratory rate, minute volume, tidal volume, mean inspiratory flow rate, and functional residual capacity.
Propofol administration also results in decreased cerebral blood flow, cerebral metabolic oxygen consumption, and intracranial pressure. In addition, propofol may decrease intraocular pressure by as much as 50% in patients with normal intraocular pressure.
A more serious but rare side effect is dystonia. Mild myoclonic movements are common, as with other intravenous hypnotic agents. Propofol appears to be safe for use in porphyria, and has not been known to trigger malignant hyperpyrexia.
Propofol is also reported to induce priapism in some individuals, and has been observed to suppress REM sleep and to worsen the poor sleep quality in some patients.
Rare side effects include:

anxiety
changes in vision
cloudy urine
coughing up blood
delirium or hallucinations
difficult urination
difficulty swallowing
dry eyes, mouth, nose, or throat
As with any other general anesthetic agent, propofol should be administered only where appropriately trained staff and facilities for monitoring are available, as well as proper airway management, a supply of supplemental oxygen, artificial ventilation, and cardiovascular resuscitation.
Because of propofol's formulation (using lecithin and soybean oil), it is prone to bacterial contamination, despite the presence of the bacterial inhibitor benzyl alcohol; consequently, some hospital facilities require the IV tubing (of continuous propofol infusions) to be changed after 12 hours. This is a preventive measure against microbial growth and potential infection.

### Propofol infusion syndrome

A rare, but serious, side effect is propofol infusion syndrome. This potentially lethal metabolic derangement has been reported in critically ill patients after a prolonged infusion of high-dose propofol, sometimes in combination with catecholamines and/or corticosteroids.

## Interactions

The respiratory effects of propofol are increased if given with other respiratory depressants, including benzodiazepines.

## Pharmacology

### Pharmacodynamics

Propofol has been proposed to have several mechanisms of action, both through potentiation of GABAA receptor activity and therefore acting as a GABAA receptor positive allosteric modulator, thereby slowing the channel-closing time. At high doses, propofol may be able to activate GABAA receptors in the absence of GABA, behaving as a GABAA receptor agonist as well. Propofol analogs have been shown to also act as sodium channel blockers. Some research has also suggested that the endocannabinoid system may contribute significantly to propofol's anesthetic action and to its unique properties, as endocannabinoids also play an important role in the physiologic control of sleep, pain processing and emesis. An EEG study on patients undergoing general anesthesia with propofol found that it causes a prominent reduction in the brain's information integration capacity.
Propofol is an inhibitor of the enzyme fatty acid amide hydrolase, which metabolizes the endocannabinoid anandamide (AEA). Activation of the endocannabinoid system by propofol, possibly via inhibition of AEA catabolism, generates a significant increase in the whole-brain content of AEA, contributing to the sedative properties of propofol via CB1 receptor activation. This may explain the psychotomimetic and antiemetic properties of propofol. By contrast, there is a high incidence of postoperative nausea and vomiting after administration of volatile anesthetics, which contribute to a significant decrease in the whole-brain content of AEA that can last up to forty minutes after induction.

### Pharmacokinetics

Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours. However, its duration of clinical effect is much shorter, because propofol is rapidly distributed into peripheral tissues. When used for IV sedation, a single dose of propofol typically wears off within minutes. Onset is rapid, in as little as 15–30 seconds. Propofol is versatile; the drug can be given for short or prolonged sedation, as well as for general anesthesia. Its use is not associated with nausea as is often seen with opioid medications. These characteristics of rapid onset and recovery along with its amnestic effects have led to its widespread use for sedation and anesthesia.

## History

John B. Glen, a veterinarian and researcher at Imperial Chemical Industries (ICI), spent thirteen years developing propofol, an effort for which he was awarded the 2018 Lasker Award for clinical research.
Originally developed as ICI 35868, propofol was chosen after extensive evaluation and structure–activity relationship studies of the anesthetic potencies and pharmacokinetic profiles of a series of ortho-alkylated phenols.
First identified as a drug candidate in 1973, propofol entered clinical trials in 1977, using a form solubilized in cremophor EL. However, due to anaphylactic reactions to cremophor, this formulation was withdrawn from the market and subsequently reformulated as an emulsion of a soya oil and propofol mixture in water. The emulsified formulation was relaunched in 1986 by ICI (whose pharmaceutical division later became a constituent of AstraZeneca) under the brand name Diprivan. The preparation contains 1% propofol, 10% soybean oil, and 1.2% purified egg phospholipid as an emulsifier, with 2.25% glycerol as a tonicity-adjusting agent, and sodium hydroxide to adjust the pH. Diprivan contains EDTA, a common chelation agent, that also acts alone (bacteriostatically against some bacteria) and synergistically with some other antimicrobial agents. Newer generic formulations contain sodium metabisulfite as an antioxidant and benzyl alcohol as an antimicrobial agent. Propofol emulsion is an opaque white fluid due to the scattering of light from the emulsified micelle formulation.

## Developments

A water-soluble prodrug form, fospropofol, has been developed and tested with positive results. Fospropofol is rapidly broken down by the enzyme alkaline phosphatase to form propofol. Marketed as Lusedra, this formulation may not produce the pain at the injection site that often occurs with the conventional form of the drug. The U.S. Food and Drug Administration (FDA) approved the product in 2008.
By incorporation of an azobenzene unit, a photoswitchable version of propofol (AP2) was developed in 2012 that allows for optical control of GABAA receptors with light. In 2013, a propofol binding site on mammalian GABAA receptors has been identified by photolabeling using a diazirine derivative. Additionally, it was shown that the hyaluronan polymer present in the synovia can be protected from free-radical depolymerization by propofol.
Ciprofol is another derivative of propofol that is 4–6 times more potent than propofol. As of 2022 it is undergoing Phase III trials. Ciprofol appears to have a lower incidence of injection site pain and respiratory depression than propofol.
Propofol has also been studied for treatment resistant depression.

## Veterinary uses

In November 2024, the US Food and Drug Administration approved PropofolVet Multidose, the first generic propofol injectable emulsion for dogs. PropofolVet Multidose is approved for use as an injectable anesthetic in dogs.
PropofolVet Multidose contains the same active ingredient (propofol injectable emulsion) as the approved brand name drug product, PropoFlo 28, which was first approved on 4 February 2011. In addition, the FDA determined that PropofolVet Multidose contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. PropofolVet Multidose is sponsored by Parnell Technologies Pty. Ltd. based in New South Wales, Australia.
`,
};
